Edwards Lifesciences Corporation (EW)
Market Cap | 52.46B |
Revenue (ttm) | 6.00B |
Net Income (ttm) | 1.40B |
Shares Out | 601.30M |
EPS (ttm) | 2.30 |
PE Ratio | 37.93 |
Forward PE | 30.76 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2,768,000 |
Open | 89.89 |
Previous Close | 90.05 |
Day's Range | 86.45 - 89.63 |
52-Week Range | 60.57 - 96.12 |
Beta | 1.07 |
Analysts | Buy |
Price Target | 92.82 (+6.4%) |
Earnings Date | Apr 25, 2024 |
About EW
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical struct... [Read more]
Financial Performance
In 2023, EW's revenue was $6.00 billion, an increase of 11.56% compared to the previous year's $5.38 billion. Earnings were $1.40 billion, a decrease of -7.85%.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for EW stock is "Buy." The 12-month stock price forecast is $92.82, which is an increase of 6.40% from the latest price.
News
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
Study of NFL Alumni Cohort Finds Majority Suffer From Heart Disease Without Knowing It
ATLANTA--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced the release of data from the HUDDLE study that examined the prevalence of heart disease and associated risk factors among members of...
Large, Real-world Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR
WASHINGTON--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today at Cardiovascular Research Technologies (CRT) 2024 the compelling results from two large, real-world studies based on TVT R...
Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare Conference
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen Healthcare Conference on Tuesday, March 5, 2024. Bernard Zovighian, chi...
Edwards Lifesciences beats quarterly estimates on strong heart device sales
Edwards Lifesciences reported fourth-quarter profit on Tuesday that beat Wall Street estimates, helped by strong demand for the company's artificial heart valves and other devices.
Edwards Lifesciences Reports Fourth Quarter Results
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2023. Highlights and Outlook Q4 sales grew 14 percent to $1.53 bill...
Edwards' EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company's EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. ...
Edwards Lifesciences to Host Earnings Conference Call on February 6, 2024
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2023 after the market closes on Tuesday, February 6, 2024, a...
Edwards Lifesciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 9, 2024. Bernard Zovighian, c...
Edwards Lifesciences To Spin-Off Critical Care Unit In 2024
On December 7, 2024, Edwards Lifesciences EW Corporation (NYSE: EW, $76.90, Market Capitalization: $46.6 billion) in its annual investor call announced its plans to spin-off its Critical Care unit int...
Edwards Lifesciences to spin off critical care unit to focus on heart devices
Edwards Lifesciences said on Thursday it would spin off its critical care unit at the end of 2024 to concentrate on its larger heart devices business.
Edwards Lifesciences to spin off Critical Care unit, sets $1B stock buyback
Edwards Lifesciences Corp.'s stock EW, +0.93% rose 1.9% in premarket trading Thursday after it said it plans to form an independent company out of its Critical Care unit in a tax-free spinoff transact...
Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) will discuss the company's sharpened focus and strategy for longer-term growth, provide an update on its technology pipelin...
CLASP IID ONE-YEAR DATA CONFIRM SAFETY AND EFFICACY OF EDWARDS PASCAL SYSTEM FOR DEGENERATIVE MITRAL REGURGITATION
SAN FRANCISCO , Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two co...
TRISCEND II SIX-MONTH DATA FOR FIRST 150 PATIENTS SUCCESSFULLY DEMONSTRATE SAFETY AND EFFICACY OF EDWARDS EVOQUE SYSTEM FOR SEVERE TRICUSPID REGURGITATION
SAN FRANCISCO , Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced successful results from TRISCEND II, a randomized controlled pivotal trial designed to evaluat...
Edwards Lifesciences quarterly sales jump on robust demand for heart devices
Edwards Lifesciences Corp on Wednesday reported a 12% rise in third-quarter sales, helped by strong demand for the company's artificial heart valves and other devices.
EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS
IRVINE, Calif. , Oct. 25, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept.
FIVE-YEAR DATA FROM PARTNER 3 TRIAL DEMONSTRATE EXCELLENT SURVIVAL FOR PATIENTS RECEIVING EDWARDS SAPIEN 3 VALVE
SAN FRANCISCO , Oct. 24, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced new data from the PARTNER 3 trial demonstrating continued low rates of all-cause mortality, disabling stro...
EDWARDS EVOQUE TRANSCATHETER TRICUSPID VALVE REPLACEMENT SYSTEM RECEIVES CE MARK
IRVINE, Calif. , Oct. 19, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced the company's EVOQUE tricuspid valve replacement system received CE Mark for the transcathete...
EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON OCTOBER 25, 2023
IRVINE, Calif. , Oct. 18, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2023 after the market closes on Wednesday, Oc...
Exclusive: Edwards Lifesciences targeted in EU antitrust raid last week - sources
Edwards Lifesciences was raided by EU antitrust regulators at one of its facilities in an EU country a week ago, two people with direct knowledge of the matter told Reuters on Tuesday.
BetterInvesting™ Magazine Update on Edwards Lifesciences Corp. and 3M Company
TROY, Mich. , Aug. 29, 2023 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Edwards Lifesciences Corp. (NYSE:EW) as its "Stock to Stu...
Will Edwards Lifesciences Stock Recover To Its Pre-Inflation Shock Highs Of $130?
Investors still have concerns about a potential recession despite a steady decline in the inflation rate in response to the Fed's aggressive rate hike plan.